ABLIM2 (actin binding LIM protein family member 2) is a cytoskeletal scaffold protein that plays important roles in actin cytoskeleton organization and transcriptional regulation. The protein contains four LIM domains in the N-terminal region and a C-terminal VHP domain, structurally similar to other ABLIM family members 1. ABLIM2 functions as a scaffold protein that may stimulate ABRA activity and ABRA-dependent SRF transcriptional activity, linking cytoskeletal dynamics to gene expression programs. The gene shows highest expression in brain and eye tissues, with high density of brain and CNS-specific transcription factor binding sites in its promoter region, suggesting particular importance in neuronal function 1. ABLIM2 demonstrates clinical relevance across multiple pathological conditions. It shows altered splicing patterns in opioid-induced hyperalgesia, particularly in the trigeminal ganglia where it functions as a transcriptional regulator 2. The protein is involved in megakaryocyte development, where ABLIM2 expression increases with DYRK1A inhibition and contributes to filamentous actin assembly and morphogenetic responses 3. Additionally, ABLIM2 variants are associated with pharmacokinetic characteristics of the anticoagulant apixaban 4, and the gene shows epigenetic modifications in selenium-cadmium antagonistic effects in breast carcinogenesis 5. These findings indicate ABLIM2's broad physiological importance in cytoskeletal organization, neuronal function, and disease processes.